The expanding role of immunotherapy in HCC скачать в хорошем качестве

The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC: combining locoregional and systemic treatments in intermediate HCC This video, developed by Prof. Aiwu Ruth He and Prof. Beau Toskich, discusses the expanding role of immunotherapy (IO) in HCC and explores treatment strategies combining locoregional treatments (LRT) and systemic treatments for intermediate HCC. Topics covered in this video include: The role of immunotherapy (IO) and IO combinations in the systemic treatment landscape for patients with unresectable HCC The scientific rationale for and expanding role of IO for patients with unresectable intermediate HCC, including multimodal approaches The safety and efficacy of IO and IO-based treatments in combination with LRTs The importance of multidisciplinary care required for the optimal treatment of patients with intermediate HCC Download the slides and summary flashcard and access the accredited e-learning here: https://cor2ed.com/hcc-connect/progra... Key clinical takeaways: IO and IO combinations are transforming the landscape for patients with advanced and intermediate HCC who are not candidates for local therapy, with 1st line options (IMbrave150, HIMALAYA) offering improved long-term outcomes, including 20% survival at 5-years in HIMALAYA Intermediate-stage HCC may benefit from multimodal strategies, combining IO with LRTs to address both visible and invisible disease, enhancing immune response and optimising tumour control IO + LRT combinations, such as TACE plus IO, show promise for patients with intermediate HCC, with positive trials like EMERALD-1 and LEAP-012 demonstrating improved PFS and manageable safety profiles, with ongoing evaluation of OS outcomes A multidisciplinary approach is crucial to determine which patients with intermediate HCC may benefit from multimodal combinations, requiring coordination among oncologists, hepatologists, interventional radiologists, radiation oncologists, and transplant surgeons Follow us on social media: LinkedIn:   / hcc-connect   X: https://x.com/hccconnectinfo This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, supporters or their institution.  AstraZeneca has provided a sponsorship grant towards this independent video. This video is developed by cor2ed.com Published in April 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.